BBLG

Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Wall Street analysts forecast BBLG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBLG is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bone Biologics Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Bone Biologics Corp. EPS for the last quarter amounts to -0.37 USD, decreased -97.40 % YoY.

Bone Biologics Corp (BBLG) has 2 emplpoyees as of December 16 2025.

Today BBLG has the market capitalization of 3.64M USD.